Not Yet Recruiting PHASE4 INTERVENTIONAL 2-arm NCT05105321

Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP) (CDPP)

Efficacy and Safety of Berberine on Primary Prevention of Cardiovascular Diseases and Diabetes in Metabolic Syndrome: a Randomized, Controlled Trial

Sponsor: Chinese Society of Cardiology

Conditions Metabolic Syndrome

Interventions Berberine Healthy lifestyle intervention

Updated 3 times since 2021 Last updated: Nov 1, 2021 Started: Dec 31, 2021 Primary completion: Dec 31, 2026 Completion: Dec 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05105321, this PHASE4 trial focuses on Metabolic Syndrome and remains actively recruiting participants. Sponsored by Chinese Society of Cardiology, it has been updated 3 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE4
Dec 2021 — Jul 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Society of Cardiology
Tang Yida

Data source: Peking University Third Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China